IMVT

Dopo l'orario di chiusura: 29.23

Immunovant Inc (IMVT)

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Immunovant Inc Stock (IMVT) Company Profile

Immunovant Inc

917-580-3099

320 WEST 37TH STREET, NEW YORK, NY

Prossima data di guadagno

Ultimi documenti SEC

IMVT's Discussions on Twitter

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-02-15	Iniziato	Wolfe Research	Outperform
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-10-13	Aggiornamento	UBS	Neutral → Buy
2023-09-26	Aggiornamento	Raymond James	Mkt Perform → Outperform
2023-05-01	Iniziato	BofA Securities	Buy
2023-04-25	Iniziato	Citigroup	Buy
2023-03-31	Iniziato	Piper Sandler	Overweight
2023-03-30	Iniziato	Stifel	Buy
2023-02-15	Iniziato	Cantor Fitzgerald	Overweight
2023-02-13	Aggiornamento	Guggenheim	Neutral → Buy
2023-01-03	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-09-26	Downgrade	UBS	Buy → Neutral
2021-12-08	Iniziato	Wells Fargo	Equal Weight
2021-08-03	Downgrade	Robert W. Baird	Outperform → Neutral
2021-08-02	Downgrade	Credit Suisse	Neutral → Underperform
2021-06-01	Downgrade	Guggenheim	Buy → Neutral
2021-06-01	Downgrade	Stifel	Buy → Hold
2020-10-28	Iniziato	UBS	Buy
2020-10-12	Iniziato	Guggenheim	Buy
2020-10-08	Iniziato	Stifel	Buy
2020-10-02	Iniziato	Credit Suisse	Outperform
2020-08-26	Reiterato	H.C. Wainwright	Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-07-29	Iniziato	H.C. Wainwright	Buy
2020-02-24	Iniziato	SVB Leerink	Outperform

Mostra tutto

Immunovant Inc Borsa (IMVT) Ultime notizie

Immunovant Inc Azioni (IMVT) Dati Finanziari

Immunovant Inc (IMVT)

Immunovant Inc Stock (IMVT) Company Profile

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Immunovant Inc Borsa (IMVT) Ultime notizie

Trading (IMVT) With Integrated Risk Controls - Stock Traders Daily

Immunovant Inc (IMVT) did well last session? - US Post News

ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Private Advisor Group LLC - Defense World

Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B - BioSpace

Quest Partners LLC Grows Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Recent Insider Activity Could Benefit Immunovant Inc (IMVT) - Knox Daily

IBRX Stock on the Rise: A Promising Investment - The InvestChronicle

WINTON GROUP Ltd Buys Shares of 20,675 Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

IVV And The S&P 500: How Bad Could It Get? (NYSEARCA:IVV) - Seeking Alpha

Headlands Technologies LLC Buys New Stake in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Immunic (NASDAQ:IMUX) Raised to Strong-Buy at EF Hutton Acquisition Co. I - MarketBeat

A new trading data show Immunovant Inc (IMVT) is showing positive returns. - SETE News

Balance Sheet Dive: Immunovant Inc (IMVT)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex

Immunovant, Inc. (NASDAQ:IMVT) Stake Lessened by Los Angeles Capital Management LLC - Defense World

Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World

Victory Capital Management Inc. Cuts Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

TD Asset Management Inc Sells 32,242 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by TD Asset Management Inc - Defense World

First Turn Management LLC Buys 182,535 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

FY2026 EPS Estimates for Immunovant, Inc. (NASDAQ:IMVT) Decreased by Analyst - Defense World

Immunovant, Inc. to Post FY2026 Earnings of ($2.82) Per Share, Leerink Partnrs Forecasts (NASDAQ:IMVT) - MarketBeat

Bank of New York Mellon Corp Has $6.61 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Bank of New York Mellon Corp - Defense World

What the Options Market Tells Us About Immunovant - Benzinga

A stock that deserves closer examination: Immunovant Inc (IMVT) - US Post News

Financial Metrics Exploration: Understanding Immunovant Inc (IMVT) Through Ratios - The Dwinnex

Immunovant’s (IMVT) Buy Rating Reaffirmed at HC Wainwright - Defense World

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab - MSN

Roivant reveals Phase 1b results for new pulmonary treatment - Investing.com

Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright - MarketBeat

Immunovant Inc (IMVT) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle

Immunovant (NASDAQ:IMVT) Given “Overweight” Rating at Cantor Fitzgerald - Defense World

Immunovant (NASDAQ:IMVT) Shares Down 3.6% - MarketBeat

Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of “Buy” from Brokerages - Defense World

Immunovant Sees Unusually High Options Volume (NASDAQ:IMVT) - Defense World

Immunovant stock falls 8% amid Graves' disease program update (NASDAQ:IMVT) - Seeking Alpha

Immunovant’s Confidence In Graves’ Disease Builds - Scrip

Immunovant (NASDAQ:IMVT) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab - Benzinga

Immunovant reports promising batoclimab trial results for Graves' Disease - Investing.com

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? - Benzinga

Immunovant Sees Unusually High Options Volume (NASDAQ:IMVT) - MarketBeat

This trade activity should not be overlooked: Immunovant Inc (IMVT) - SETE News

Top 2 Health Care Stocks That May Collapse This Quarter - Benzinga

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses - Pharmaceutical Technology

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab - Yahoo Finance

Immunovant Advances Groundbreaking Therapy in Graves’ Disease Trials - TipRanks

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses - Yahoo Finance

Roivant Provides Update on Graves’ Disease Development Program - ForexTV.com

Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses - Clinical Trials Arena

Immunovant Inc Azioni (IMVT) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a IMVT